A New Drug Is Developed That Targets and Binds to the Lipid

A new drug is developed that targets and binds to the lipid A portion of LPS from Gram-negative bacterial cells. This drug shows a high degree of activity and binding in a test tube setting against purified lipid A. Based on this information,

A) we should fast track this drug and get it out to physicians immediately to help prevent toxic/septic shock in humans.
B) we should do some animal testing with whole Gram-negative cells and the drug before we jump to any conclusions.
C) we should next proceed by moving to testing in a test tube using whole Gram-negative cells to see if it binds with the same strength.
D) we should abandon the drug entirely. Binding to lipid A won't kill the bacteria, so the drug is useless to develop further. It wouldn't help humans who have septic shock at all.